nach oben

Endocrine

Erschienen in:

09.05.2016 | Original Article

Inhibition of tumor suppressor p53 preserves glycation-serum induced pancreatic beta-cell demise

verfasst von: Y. Li, T. Zhang, Q. Huang, Y. Sun, X. Chang, H. Zhang, Y. Zhu, X. Han

Erschienen in: Endocrine | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Tumor suppressor p53 is a transcriptional factor that determines cell fate in response to multiple stressors, such as oxidative stress and endoplasmic reticulum stress, in the majority of cells. However, its role in pancreatic beta cells is not well documented. Our previous research has revealed that glycation-serum (GS) induced pancreatic beta-cell demise through the AGEs-RAGE pathway. In the present study, we investigated the role of p53 in GS-related beta-cell demise. Using pancreatic islets beta-cell line INS-1 cells, we found that with GS treatment, the transcriptional activity of p53 was significantly evoked due to the increased amount of nuclear p53 protein. Resveratrol (RSV) was capable of further enhancing this transcriptional ability and consequently increased the population of dead beta cells under GS exposure. In contrast, inhibiting this transcriptional activity via p53 interference greatly protected beta cells from the damage provoked by GS, as well as damage strengthened by RSV. However, the pharmacological activation of PPARγ with troglitazone (TRO) only suppressed GS-induced, not RSV-induced, p53 activity. Moreover, the activation of PPARγ greatly preserved beta cells from GS-induced death. This protective effect recurred due to improved mitochondrial function with Bcl2 overexpression. Further, p53 activation could induce cellular apoptosis in primary rat islets. Our findings explore the broader role of p53 in regulating pancreatic beta-cell demise in the presence of GS and may provide a therapeutic target for the treatment and prevention of diabetes.

Nur mit Berechtigung zugänglich

Z. Fu, E.R. Gilbert, D. Liu, Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr. Diabetes Rev. 9, 25–53 (2013)CrossRefPubMedPubMedCentral

S. Cernea, M. Dobreanu, Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochemia Medica 23, 266–280 (2013)CrossRefPubMedPubMedCentral

Y. Hirasawa, Y. Matsui, S. Ohtsu, K. Yamane, T. Toyoshi, K. Kyuki, T. Sakai, Y. Feng, T. Nagamatsu, Involvement of hyperglycemia in deposition of aggregated protein in glomeruli of diabetic mice. Eur. J. Pharmacol. 601, 129–135 (2008)CrossRefPubMed

K. Nowotny, T. Jung, A. Hohn, D. Weber, T. Grune, Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 5, 194–222 (2015)CrossRefPubMedPubMedCentral

J. O’Brien, P.A. Morrissey, Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit. Rev. Food Sci. Nutr. 28, 211–248 (1989)CrossRefPubMed

R. Ramasamy, S.J. Vannucci, S.S. Yan, K. Herold, S.F. Yan, A.M. Schmidt, Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15, 16R–28R (2005)CrossRefPubMed

H. Vlassara, G.E. Striker, Advanced glycation end products in diabetes and diabetic complications. Endocrinol. Metab. Clin. N. Am. 42, 697–719 (2013)CrossRef

R. Pokupec, M. Kalauz, N. Turk, Z. Turk, Advanced glycation end products in human diabetic and non-diabetic cataractous lenses. Graefes. Arch. Clin. Exp. Ophthalmol. 241, 378–384 (2003)CrossRefPubMed

O. Sandu, K. Song, W. Cai, F. Zheng, J. Uribarri, H. Vlassara, Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 54, 2314–2319 (2005)CrossRefPubMed

10.

E.J. Gallagher, D. LeRoith, E. Karnieli, The metabolic syndrome-from insulin resistance to obesity and diabetes. Endocrinol. Metab. Clin. N. Am. 37, 559–579 (2008)CrossRef

11.

W. Cai, M. Ramdas, L. Zhu, X. Chen, G.E. Striker, H. Vlassara, Oral advanced glycation end products (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc. Natl. Acad. Sci. USA 109, 15888–15893 (2012)CrossRefPubMedPubMedCentral

12.

G. Luciano Viviani, A. Puddu, G. Sacchi, A. Garuti, D. Storace, A. Durante, F. Monacelli, P. Odetti, Glycated fetal calf serum affects the viability of an insulin-secreting cell line in vitro. Metabolism. 57, 163–169 (2008)CrossRefPubMed

13.

X. Kong, G.D. Wang, M.Z. Ma, R.Y. Deng, L.Q. Guo, J.X. Zhang, J.R. Yang, Q. Su, Sesamin ameliorates advanced glycation end products-induced pancreatic beta-cell dysfunction and apoptosis. Nutrients 7, 4689–4704 (2015)CrossRefPubMedPubMedCentral

14.

J. Uribarri, W. Cai, M. Ramdas, S. Goodman, R. Pyzik, X. Chen, L. Zhu, G.E. Striker, H. Vlassara, Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34, 1610–1616 (2011)CrossRefPubMedPubMedCentral

15.

H. Vlassara, G.E. Striker, AGE restriction in diabetes mellitus: a paradigm shift. Nat. Rev. Endocrinol. 7, 526–539 (2011)CrossRefPubMedPubMedCentral

16.

C. Luevano-Contreras, M.E. Garay-Sevilla, K. Wrobel, J.M. Malacara, K. Wrobel, Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J. Clin. Biochem. Nutr. 52, 22–26 (2013)CrossRefPubMed

17.

A. Puddu, R. Sanguineti, A. Durante, A. Nencioni, F. Mach, F. Montecucco, G.L. Viviani, Glucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum. Mediat. Inflamm. 2013, 317120 (2013)

18.

T. Shu, Y. Zhu, H. Wang, Y. Lin, Z. Ma, X. Han, AGEs decrease insulin synthesis in pancreatic beta-cell by repressing Pdx-1 protein expression at the post-translational level. PLoS ONE 6, e18782 (2011)CrossRefPubMedPubMedCentral

19.

Y. Zhu, T. Shu, Y. Lin, H. Wang, J. Yang, Y. Shi, X. Han, Inhibition of the receptor for advanced glycation end products (RAGE) protects pancreatic beta-cells. Biochem. Biophys. Res. Commun. 404, 159–165 (2011)CrossRefPubMed

20.

L. Jiang, J.H. Hickman, S.J. Wang, W. Gu, Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses. Cell Cycle 14, 2881–2885 (2015)CrossRefPubMedPubMedCentral

21.

N. Sen, Y.K. Satija, S. Das, PGC-1alpha, a key modulator of p53, promotes cell survival upon metabolic stress. Mol. Cell 44, 621–634 (2011)CrossRefPubMed

22.

S.E. Thomas, E. Malzer, A. Ordonez, L.E. Dalton, E.F. van ‘t Wout, E. Liniker, D.C. Crowther, D.A. Lomas, S.J. Marciniak, p53 and translation attenuation regulate distinct cell cycle checkpoints during endoplasmic reticulum (ER) stress. J. Biol. Chem. 288, 7606–7617 (2013)CrossRefPubMedPubMedCentral

23.

M. Oren, Decision making by p53: life, death and cancer. Cell Death Differ. 10, 431–442 (2003)CrossRefPubMed

24.

Z. Li, M. Ni, J. Li, Y. Zhang, Q. Ouyang, C. Tang, Decision making of the p53 network: death by integration. J. Theor. Biol. 271, 205–211 (2011)CrossRefPubMed

25.

S. Zhang, J. Liu, E.L. Saafi, G.J. Cooper, Induction of apoptosis by human amylin in RINm5F islet beta-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. FEBS Lett. 455, 315–320 (1999)CrossRefPubMed

26.

P. Lovis, E. Roggli, D.R. Laybutt, S. Gattesco, J.Y. Yang, C. Widmann, A. Abderrahmani, R. Regazzi, Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 57, 2728–2736 (2008)CrossRefPubMedPubMedCentral

27.

H. Yuan, X. Zhang, X. Huang, Y. Lu, W. Tang, Y. Man, S. Wang, J. Xi, J. Li, NADPH oxidase 2-derived reactive oxygen species mediate FFAs-induced dysfunction and apoptosis of beta-cells via JNK, p38 MAPK and p53 pathways. PLoS ONE 5, e15726 (2010)CrossRefPubMedPubMedCentral

28.

V.B. Cismasiu, J. Duque, E. Paskaleva, D. Califano, S. Ghanta, H.A. Young, D. Avram, BCL11B enhances TCR/CD28-triggered NF-kappaB activation through up-regulation of Cot kinase gene expression in T-lymphocytes. Biochem. J. 417, 457–466 (2009)CrossRefPubMedPubMedCentral

29.

Y. Lin, X. Tang, Y. Zhu, T. Shu, X. Han, Identification of PARP-1 as one of the transcription factors binding to the repressor element in the promoter region of COX-2. Arch. Biochem. Biophys. 505, 123–129 (2011)CrossRefPubMed

30.

S.D. Varma, P.S. Devamanoharan, A.H. Ali, Formation of advanced glycation end (AGE) products in diabetes: prevention by pyruvate and alpha-ketoglutarate. Mol. Cell. Biochem. 171, 23–28 (1997)CrossRefPubMed

31.

L.B. Lingelbach, A.E. Mitchell, R.B. Rucker, R.B. McDonald, Accumulation of advanced glycation end products in aging male Fischer 344 rats during long-term feeding of various dietary carbohydrates. J. Nutr. 130, 1247–1255 (2000)PubMed

32.

Z. Zhao, C. Zhao, X.H. Zhang, F. Zheng, W. Cai, H. Vlassara, Z.A. Ma, Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 150, 2569–2576 (2009)CrossRefPubMedPubMedCentral

33.

M.T. Coughlan, F.Y. Yap, D.C. Tong, S. Andrikopoulos, A. Gasser, V. Thallas-Bonke, D.E. Webster, J. Miyazaki, T.W. Kay, R.M. Slattery, D.M. Kaye, B.G. Drew, B.A. Kingwell, S. Fourlanos, P.H. Groop, L.C. Harrison, M. Knip, J.M. Forbes, Advanced glycation end products are direct modulators of beta-cell function. Diabetes 60, 2523–2532 (2011)CrossRefPubMedPubMedCentral

34.

Y. Zhu, A. Ma, H. Zhang, C. Li, PPARgamma activation attenuates glycated-serum induced pancreatic beta-cell dysfunction through enhancing Pdx1 and Mafa protein stability. PLoS ONE 8, e56386 (2013)CrossRefPubMedPubMedCentral

35.

Ge QM, Dong Y, Su Q. Effects of glucose and advanced glycation end products on oxidative stress in MIN6 cells. Cell Mol Biol (Noisy-le-grand). 2010; 56 Suppl: OL1231-8

36.

A.K. Mohamed, A. Bierhaus, S. Schiekofer, H. Tritschler, R. Ziegler, P.P. Nawroth, The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 10, 157–167 (1999)CrossRefPubMed

37.

K.C. Lan, C.Y. Chiu, C.W. Kao, K.H. Huang, C.C. Wang, K.T. Huang, K.S. Tsai, M.L. Sheu, S.H. Liu, Advanced glycation end-products induce apoptosis in pancreatic islet endothelial cells via NF-kappaB-activated cyclooxygenase-2/prostaglandin E2 up-regulation. PLoS ONE 10, e0124418 (2015)CrossRefPubMedPubMedCentral

38.

D. Melloul, Role of NF-kappaB in beta-cell death. Biochem. Soc. Trans. 36, 334–339 (2008)CrossRefPubMed

39.

C. Arous, P.G. Ferreira, E.T. Dermitzakis, P.A. Halban, Short term exposure of beta cells to low concentrations of interleukin-1beta improves insulin secretion through focal adhesion and actin remodeling and regulation of gene expression. J. Biol. Chem. 290, 6653–6669 (2015)CrossRefPubMedPubMedCentral

40.

M. Cnop, N. Welsh, J.C. Jonas, A. Jorns, S. Lenzen, D.L. Eizirik, Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(Suppl 2), S97–S107 (2005)CrossRefPubMed

41.

M.Y. Donath, J. Storling, K. Maedler, T. Mandrup-Poulsen, Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med. 81, 455–470 (2003)CrossRefPubMed

42.

I. Rakatzi, H. Mueller, O. Ritzeler, N. Tennagels, J. Eckel, Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47, 249–258 (2004)CrossRefPubMed

43.

K. Maedler, P. Sergeev, F. Ris, J. Oberholzer, H.I. Joller-Jemelka, G.A. Spinas, N. Kaiser, P.A. Halban, M.Y. Donath, Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851–860 (2002)CrossRefPubMedPubMedCentral

44.

I. Kharroubi, L. Ladriere, A.K. Cardozo, Z. Dogusan, M. Cnop, D.L. Eizirik, Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 145, 5087–5096 (2004)CrossRefPubMed

45.

J. Buteau, W. El-Assaad, C.J. Rhodes, L. Rosenberg, E. Joly, M. Prentki, Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47, 806–815 (2004)CrossRefPubMed

46.

F. Xin, L. Jiang, X. Liu, C. Geng, W. Wang, L. Zhong, G. Yang, M. Chen, Bisphenol A induces oxidative stress-associated DNA damage in INS-1 cells. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 769, 29–33 (2014)CrossRefPubMed

47.

S. Tornovsky-Babeay, D. Dadon, O. Ziv, E. Tzipilevich, T. Kadosh, R. Schyr-Ben Haroush, A. Hija, M. Stolovich-Rain, J. Furth-Lavi, Z. Granot, S. Porat, L.H. Philipson, K.C. Herold, T.R. Bhatti, C. Stanley, F.M. Ashcroft, P. In’t Veld, A. Saada, M.A. Magnuson, B. Glaser, Y. Dor, Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells. Cell Metab. 19, 109–121 (2014)CrossRefPubMed

48.

D.A. Cunha, M. Igoillo-Esteve, E.N. Gurzov, C.M. Germano, N. Naamane, I. Marhfour, M. Fukaya, J.M. Vanderwinden, C. Gysemans, C. Mathieu, L. Marselli, P. Marchetti, H.P. Harding, D. Ron, D.L. Eizirik, M. Cnop, Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human beta-cell apoptosis. Diabetes 61, 2763–2775 (2012)CrossRefPubMedPubMedCentral

49.

O.D. Maddocks, C.R. Berkers, S.M. Mason, L. Zheng, K. Blyth, E. Gottlieb, K.H. Vousden, Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542–546 (2013)CrossRefPubMed

50.

C. Evans-Molina, R.D. Robbins, T. Kono, S.A. Tersey, G.L. Vestermark, C.S. Nunemaker, J.C. Garmey, T.G. Deering, S.R. Keller, B. Maier, R.G. Mirmira, Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure. Mol. Cell. Biol. 29, 2053–2067 (2009)CrossRefPubMedPubMedCentral

51.

K.K. Brown, B.R. Henke, S.G. Blanchard, J.E. Cobb, R. Mook, I. Kaldor, S.A. Kliewer, J.M. Lehmann, J.M. Lenhard, W.W. Harrington, P.J. Novak, W. Faison, J.G. Binz, M.A. Hashim, W.O. Oliver, H.R. Brown, D.J. Parks, K.D. Plunket, W.Q. Tong, J.A. Menius, K. Adkison, S.A. Noble, T.M. Willson, A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48, 1415–1424 (1999)CrossRefPubMed

52.

J.S. Wu, T.N. Lin, K.K. Wu, Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J. Cell. Physiol. 220, 58–71 (2009)CrossRefPubMed

53.

Y. Ren, C. Sun, Y. Sun, H. Tan, Y. Wu, B. Cui, Z. Wu, PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul. Pharmacol. 51, 169–174 (2009)CrossRefPubMed

54.

J.C. Strum, R. Shehee, D. Virley, J. Richardson, M. Mattie, P. Selley, S. Ghosh, C. Nock, A. Saunders, A. Roses, Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis. 11, 45–51 (2007)PubMed

Titel: Inhibition of tumor suppressor p53 preserves glycation-serum induced pancreatic beta-cell demise
verfasst von: Y. Li
T. Zhang
Q. Huang
Y. Sun
X. Chang
H. Zhang
Y. Zhu
X. Han
Publikationsdatum: 09.05.2016
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-016-0979-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Effectiveness of a diet with low advanced glycation end products, in improving glycoxidation and lipid peroxidation: a long-term investigation in patients with chronic renal failure

Oxytocin in survivors of childhood-onset craniopharyngioma

A hypothetical model to solve the controversy over the involvement of UCP2 in palmitate-induced β-cell dysfunction

Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty

High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures